Photo for representation purposes only. (Source: Reuters) 
Special 
Photo for representation purposes only. (Source: Reuters) Lupin, Mumbai-based drug firm, has received approval form the United States Food and Drug Administration (USFDA) to sell in the US a generic version of ViiV Healthcare's Epivir Tablets, used in treating HIV infection.
The home-grown pharma major has received final approval from the US health regulator for its Lamivudine tablets in strengths of 150 mg and 300 mg, Lupin said in a statement.
Lupin Pharmaceuticals (LPI), the company's US subsidiary, would commence marketing the product shortly, the drug firm added.
Epivir tablets are indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection. According to IMS MAT September 2014 sales data, Epivir tablets had annual sales of US $39.7 million in the US.
Lupin's stock was trading 0.12 per cent lower from their previous close, at Rs 1,401 a piece on the Bombay Stock Exchange.
2014 YEAR IN REVIEW: What made buzz in 2014
Copyright©2025 Living Media India Limited. For reprint rights: Syndications Today
